| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M201266200 |
| P8608 | Fatcat ID | release_vfwf66aoibejzeqandaavry6oq |
| P698 | PubMed publication ID | 11854300 |
| P50 | author | Joachim Lingner | Q55302211 |
| P2093 | author name string | Andreas Schnapp | |
| Christian Wenz | |||
| Wolfgang J Rettig | |||
| Henning Priepke | |||
| Norbert Hauel | |||
| Pilar Garin-Chesa | |||
| Klaus Damm | |||
| Emanuelle Pascolo | |||
| Iris Kauffmann | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| A telomerase component is defective in the human disease dyskeratosis congenita | Q22010917 | ||
| Human telomerase contains two cooperating telomerase RNA molecules | Q24291388 | ||
| hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization | Q24310670 | ||
| Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT | Q24313396 | ||
| Extension of life-span by introduction of telomerase into normal human cells | Q24336088 | ||
| The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats | Q24339608 | ||
| Telomere shortening and apoptosis in telomerase-inhibited human tumor cells | Q24598974 | ||
| Human telomerase contains evolutionarily conserved catalytic and structural subunits | Q24604009 | ||
| Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors | Q27729428 | ||
| Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance | Q27766086 | ||
| Specific Association of Human Telomerase Activity with Immortal Cells and Cancer | Q27860801 | ||
| Functional requirement of p23 and Hsp90 in telomerase complexes | Q28115669 | ||
| Reconstitution of human telomerase activity in vitro | Q28116966 | ||
| Creation of human tumour cells with defined genetic elements | Q28141602 | ||
| A highly selective telomerase inhibitor limiting human cancer cell proliferation | Q29301431 | ||
| Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor | Q29547710 | ||
| A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis | Q29614741 | ||
| A survey of telomerase activity in human cancer | Q29614858 | ||
| Reverse transcriptase motifs in the catalytic subunit of telomerase | Q29618392 | ||
| A mutant of Tetrahymena telomerase reverse transcriptase with increased processivity | Q30305651 | ||
| Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase | Q33966749 | ||
| Functional multimerization of the human telomerase reverse transcriptase | Q33969441 | ||
| Telomerase inhibitors | Q34141402 | ||
| Template definition by Tetrahymena telomerase reverse transcriptase | Q34487376 | ||
| Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines | Q36556649 | ||
| Functional analysis of conserved residues in the putative "finger" domain of telomerase reverse transcriptase | Q38296299 | ||
| One-step affinity purification protocol for human telomerase | Q39724301 | ||
| Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products | Q39726040 | ||
| Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA. | Q43153047 | ||
| Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays | Q45772570 | ||
| Inhibition of human telomerase activity by peptide nucleic acids | Q47960865 | ||
| Inhibition of telomerase limits the growth of human cancer cells. | Q52536487 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 15566-15572 | |
| P577 | publication date | 2002-02-19 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate | |
| P478 | volume | 277 |
| Q35969867 | A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus |
| Q34414940 | A small molecule inhibitor of Pot1 binding to telomeric DNA. |
| Q36803215 | A translocation-defective telomerase with low levels of activity and processivity stabilizes short telomeres and confers immortalization |
| Q34632410 | A yeast chemical genetic screen identifies inhibitors of human telomerase |
| Q47136781 | BRD4 inhibitors block telomere elongation |
| Q56507869 | BRD4 inhibitors block telomere elongation |
| Q38819605 | Beyond Telomerase: Telomere Instability as a Novel Target for Cancer Therapy |
| Q33814333 | Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. |
| Q34785917 | Chondrocyte senescence and telomere regulation: implications in cartilage aging and cancer (a brief review). |
| Q37146556 | Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer |
| Q33906673 | Combating oxidative stress as a hallmark of cancer and aging: Computational modeling and synthesis of phenylene diamine analogs as potential antioxidant |
| Q33637957 | Computationally designed peptide inhibitors of the ubiquitin E3 ligase SCF(Fbx4). |
| Q39967658 | Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines |
| Q96607407 | Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives |
| Q46040321 | DNA-binding determinants and cellular thresholds for human telomerase repeat addition processivity. |
| Q36121451 | Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines |
| Q39413812 | Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. |
| Q41168816 | Discovery of (4-bromophenyl)(3-hydroxy-4-methoxyphenyl)methanone through upregulating hTERT induces cell apoptosis and ERS. |
| Q35892131 | Does the reservoir for self-renewal stem from the ends? |
| Q52652673 | Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells. |
| Q37619108 | Epstein-Barr virus and telomerase: from cell immortalization to therapy |
| Q39250400 | Facile synthesis of naphthoquinone spiroketals by diastereoselective oxidative [3 + 2] cycloaddition |
| Q42203298 | Glucose restriction decreases telomerase activity and enhances its inhibitor response on breast cancer cells: possible extra-telomerase role of BIBR 1532. |
| Q33554104 | Human MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells |
| Q51764559 | Human RTEL1 stabilizes long G-overhangs allowing telomerase-dependent over-extension. |
| Q42107167 | Human telomerase specialization for repeat synthesis by unique handling of primer-template duplex |
| Q30771484 | Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells |
| Q38289652 | Identification of an RNA aptamer binding hTERT-derived peptide and inhibiting telomerase activity in MCF7 cells |
| Q35626186 | Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT. |
| Q36346931 | Induction of senescence in cancer cells by the G-quadruplex stabilizer, BMVC4, is independent of its telomerase inhibitory activity |
| Q73173568 | Inhibition of telomerase by BIBR 1532 and related analogues |
| Q30457044 | Inhibition of telomerase recruitment and cancer cell death |
| Q51541879 | Kinetics of DNA replication and telomerase reaction at a single-seeded telomere in human cells. |
| Q37702172 | Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. |
| Q47938086 | Loss of Tumor Suppressor STAG2 Promotes Telomere Recombination and Extends the Replicative Lifespan of Normal Human Cells |
| Q81348475 | Low- to high-throughput analysis of telomerase modulators with Telospot |
| Q89475689 | Mechanisms of template handling and pseudoknot folding in human telomerase and their manipulation to expand the sequence repertoire of processive repeat synthesis |
| Q90108562 | Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer |
| Q47184251 | New perspectives on telomerase RNA structure and function |
| Q94586161 | Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma |
| Q97069904 | Persistent telomere cohesion protects aged cells from premature senescence |
| Q31138239 | Potent Inhibition of Human Telomerase by Nitrostyrene Derivatives |
| Q34769921 | Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. |
| Q38839309 | Recent advances in targeting the telomeric G-quadruplex DNA sequence with small molecules as a strategy for anticancer therapies |
| Q34056440 | Recombinogenic telomeres in diploid Sorex granarius (Soricidae, Eulipotyphla) fibroblast cells. |
| Q35125971 | Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer |
| Q34050439 | Roles for RNA in telomerase nucleotide and repeat addition processivity |
| Q44289559 | Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase |
| Q37603448 | Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells |
| Q49379504 | Stabilization of Reversed Replication Forks by Telomerase Drives Telomere Catastrophe |
| Q92495595 | Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity |
| Q38835615 | Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532 |
| Q89597527 | Structural Features of Nucleoprotein CST/Shelterin Complex Involved in the Telomere Maintenance and Its Association with Disease Mutations |
| Q38855247 | Synthesis and biological evaluation of hybrid acridine-HSP90 ligand conjugates as telomerase inhibitors |
| Q38809785 | Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents |
| Q89526241 | Targeted Covalent Inhibition of Telomerase |
| Q39437568 | Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells |
| Q33383955 | Targeting human telomerase for cancer therapeutics. |
| Q40126773 | Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors |
| Q37750789 | Targeting telomerase in hematologic malignancy |
| Q38744397 | Targeting telomerase with radiolabeled inhibitors. |
| Q37825614 | Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. |
| Q64084319 | Telomerase Deficiency Predisposes to Heart Failure and Ischemia-Reperfusion Injury |
| Q39111969 | Telomerase Mechanism of Telomere Synthesis |
| Q24680286 | Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita |
| Q37078833 | Telomerase and cancer therapeutics |
| Q64228494 | Telomerase and poly(ADP-ribose) polymerase-1 activity sensing based on the high fluorescence selectivity and sensitivity of TOTO-1 towards G bases in single-stranded DNA and poly(ADP-ribose) |
| Q37859251 | Telomerase and the endocrine system |
| Q35131774 | Telomerase and tumorigenesis |
| Q28079188 | Telomerase as a Cancer Target. Development of New Molecules |
| Q31125909 | Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes |
| Q34198649 | Telomerase inhibition as cancer therapy. |
| Q39283577 | Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q26786613 | Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase |
| Q36103191 | Telomere and telomerase as targets for anti-cancer and regeneration therapies |
| Q36832376 | Telomere biology of pediatric cancer |
| Q36556488 | Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover |
| Q34743340 | Telomere maintenance as a target for anticancer drug discovery |
| Q34426966 | Telomere maintenance mechanisms in cancer: clinical implications |
| Q48311718 | Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine |
| Q37705182 | Telomeres and telomerase in normal and malignant B-cells. |
| Q98158989 | Telomeres and telomerase in oncogenesis |
| Q30433767 | The Euplotes telomerase subunit p43 stimulates enzymatic activity and processivity in vitro |
| Q38288312 | The cellular senescence of leukemia-initiating cells from acute lymphoblastic leukemia is postponed by β-Arrestin1 binding with P300-Sp1 to regulate hTERT transcription. |
| Q26825221 | The impact of cellular senescence in cancer therapy: is it true or not? |
| Q34146428 | The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase |
| Q27027457 | Therapeutic targeting of replicative immortality |
| Q90353766 | Therapies targeting the signal pathways of pheochromocytoma and paraganglioma |
| Q36940666 | Vascular Actions of Angiotensin 1-7 in the Human Microcirculation: Novel Role for Telomerase |
| Q33439232 | siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells |
Search more.